Background: Protein intake may influence important health outcomes in later life.
Introduction
Overweight and obesity are among the most serious public health challenges. The effectiveness of different treatment modalities is limited, and, thus, interest in the identification of modifiable risk and protective factors is growing. One of these includes research on the potential role of infant feeding on body composition and the likelihood of being overweight or obese in later life.
Sufficient protein intake early in life is of major importance. Deficient protein intake can lead to suboptimal growth and impaired neurodevelopment (1) . However, protein intake that is too high may have adverse effects as well. It has been documented that rapid weight gain in infancy is associated with an increased chance of later obesity (2) , and weight gain from birth to 24 mo is the best overall predictor of later overweight (3) . High early protein intake in excess of metabolic requirements may stimulate the secretion of insulin and insulinlike growth factor I (4), thereby enhancing weight gain in infancy and increasing the later risk of obesity. This is known as the early protein hypothesis (5) , and it is based on early observations by Rolland-Cachera et al. (6) . These investigators related a high protein intake during early childhood to modified endocrine responses and an increased risk of obesity at school age. The mechanisms by which increased protein intake affects weight gain and body composition are not yet completely clear. However, the endocrine and metabolic responses of infants are affected substantially by dietary protein intake (7) . Therefore, lowering protein intake from milk formulas may exhibit beneficial effects on weight gain, body composition, and metabolic diseases in later life.
There is currently no consensus regarding what should be the appropriate amount of protein in infant formulas (8) (9) (10) (11) (12) . European Directive 2006/141/EC on infant and follow-on formulas (13) , as well as the FDA (14) , Codex Alimentarius (15) , and European Food Safety Authority (16) , define the minimum protein-to-energy ratio for infant formulas based on cow milk and soy protein as 1.8 g/100 kcal and 2.25 g/100 kcal, respectively, but they do not define an optimal intake amount.
In 2014, the European Food Safety Authority carried out a literature search and review as preparatory work for the evaluation of the composition of infant and follow-on formulas and growing-up milk. With regard to reduced-protein formulas, this report concluded that neither negative health effects nor clear benefits from the use of this type of formula could be established (8) . Because there is uncertainty regarding the effect of dietary protein intake in childhood on growth and body composition, and the later risk of overweight, obesity, and metabolic syndrome, we aimed to investigate systematically the current evidence on this proposed relation. The review protocol was registered on the PROSPERO International Prospective Register for Systematic Reviews (crd.york.ac.uk/prospero/ index.asp) as CRD42014015573.
Methods
Inclusion/exclusion criteria. Study inclusion and exclusion criteria are summarized in Table 1 (CRD42014015573) .
Search methods for identification of studies. The following electronic databases were searched until November 2014 for published studies that fulfilled our criteria: Cochrane Central Register of Controlled Trials, PubMed (including MEDLINE), Embase, and the Cumulative Index to Nursing and Allied Health Literature. To identify potential systematic reviews/meta-analyses, we browsed The Cochrane Database of Systematic Reviews and Database of Abstracts of Reviews of Effects.
Four reviewers (BP-G, BMZ, SMPK, and JK) were involved in the process of the search, which was carried out independently by at least 2 reviewers. No language restrictions were applied. A detailed search strategy (Supplemental Table 1 ) was prepared with the support of an information specialist from the Centre for Reviews and Dissemination, University of York. Initially, the title, abstract, and keywords of every record identified with the use of our search strategy were screened. Irrelevant articles were excluded by title or abstract. Full texts were obtained for all potentially relevant studies. Differences between reviewers were resolved by discussion until a consensus was reached. The reference lists from identified studies and key review articles, as well as selected trial registries (clinicaltrials.gov, www.clinicaltrials.gov; EU Clinical Trials Register, www.clinicaltrialsregister.eu), were searched. Proceedings from major scientific gastrointestinal and nutritional meetings published in the last 3 y also were screened. Finally, an attempt was made to obtain additional data by direct contact with experts in the field.
Data collection and analysis. An initial screening of the title, abstract, and keywords of every record identified was performed. The next step was to retrieve the full text of potentially relevant studies. Three reviewers (BP-G, BMZ, and JK) independently assessed the eligibility of each potentially relevant study with the use of the inclusion criteria. All cases in which different opinions or questions about the eligibility of a particular study occurred were discussed with at least one other member of the group (usually the expert of the team).
Data extraction and management. With the use of a previously prepared template of a table of evidence, 2 reviewers independently extracted the data necessary for study characteristics and risk of bias assessment.
Assessment of risk of bias. The Cochrane CollaborationÕs tool for assessing risk of bias was used while including the following criteria: adequacy of sequence generation; allocation concealment; blinding of participants, personnel, and outcome assessors; incomplete outcome data; and selective reporting.
Measures of treatment effect. If feasible, for the continuous outcomes, the results have been reported as the mean difference (MD) 8 between the lower-protein formula groups and higher-protein formula groups with a 95% CI. For the dichotomous outcome (prevalence of obesity), the results have been reported as the RR between the lowerprotein and higher-protein formula groups with a 95% CI. Missing SDs in 2 randomized controlled trials (RCTs) were calculated based on the reported SEMs with the use of the method described in the Cochrane Handbook for Systematic Reviews of Interventions (17) . For outcomes expressed with the use of different units, if possible, data were transformed for their unification (e.g., millimeters into centimeters). Four authors were contacted by e-mail or personally to obtain missing data or clarify equivocal issues. This resulted in our obtaining additional unpublished data from 2 published trials (18, 19) .
Assessment of heterogeneity. Clinical and methodologic inconsistency between the selected studies was assessed during the initial analysis, data extraction, and quality assessment process. The decision to pool data together into a meta-analysis was based mainly on this assessment. Additional information about heterogeneity was obtained when the results of the chi-square test and I 2 value were analyzed for some outcomes.
Assessment of reporting biases. Although originally planned, because of the insufficient number of studies included in the metaanalysis (<10), we did not create a funnel plot, nor did we perform a statistical test for its asymmetry to detect potential publication bias. (18, (20) (21) (22) , in order to avoid a unit-of-analysis error, we combined the study groups to achieve a single pairwise comparison while following the formulas provided by the Cochrane Handbook for Systematic Reviews of Interventions (17) . Some studies, although reporting an outcome of interest, were excluded from the meta-analysis because of a lack of necessary data (a lack of sample size, narrative results description without numerical data, etc.). The authors of one trial assessed the outcomes for lower-and higher-protein formula groups at different ages of children; thus, this trial was excluded from the analysis (23) . In the case of another study, we could not rule out the possibility of the presentation of duplicated data (21) . However, because data from this study were not pooled together in the metaanalysis with data provided by other authors, the inclusion of this study is unlikely to result in biased estimates. The study aimed to compare infants that were given different weaning foods (Swedish or Mediterranean); however, children in both groups were randomly assigned to receive formula with a lower or higher protein concentration. Because the authors provided sufficient data, we compared the growth of infants within each study group (different protein concentrations), but not between the groups themselves (different weaning food). In the case of one trial [Raiha et al. (24) ], when presenting the results, we made an assumption that the mean values were accompanied by SD values (but not SEM values). However, this was not clearly stated in the original paper.
Results
For a PRISMA flow diagram documenting the identification process for eligible trials, see online Supplemental Figure 1 . For the characteristics of the excluded trials, with reasons for exclusion, see online Supplemental Table 2 . The characteristics of 17 included publications describing 12 trials (10 RCTs and 2 quasi-randomized trials) (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) (28) (29) (30) (31) (32) (33) (34) are summarized in Table 2 . Six of the 17 selected publications reported the results of the EU Childhood Obesity Program (CHOP) study (19, (30) (31) (32) (33) (34) . All study participants were healthy, term infants. The majority of children were from birth to 4 mo of age at enrollment and exclusively formula-fed during the first months of life. Except for 2 trials conducted in China (25, 26) , the included trials were undertaken in Europe.
The protein concentration in different infant formulas varied greatly between the studies, ranging from 1.1 to 2.1 g/100 mL in the lower-protein formula group to 1.5 to 3.2 g/100 mL in the higherprotein formula group. In one trial (28), the protein concentration was unreported (described as low-and high-protein formulas). Differences in the types of protein used with respect to the whey-tocasein ratio were observed between the studies and between the study groups within individual studies. Some of the included studies were multiarm studies with >2 intervention groups. Two separate studies by Lonnerdal and Chen (25, 26) involved the same population of infants observed during different time periods (from birth and from 4 mo of age). In addition, in many trials, a reference group of breastfed infants was recruited. The duration of the intervention usually lasted between 3 and 5 mo, with the exception of that in the CHOP study, in which infants received study formula until 12 mo of age. Also, The CHOP study was the only identified study with a longer (>12 mo of age) follow-up. Mixed feeding groups (breastfed and concurrently formulafed children), if formula feeding was a predominant source of milk Formula with a protein from a different source (soy, rice, hydrolyzed, elemental, etc.)
The differences in composition of amino acids and/or macronutrients that were secondary to the protein amount modification (in order to achieve an isocaloric formula) were not considered as an actual additional modification that disqualifies the study from inclusion by guest on November 9, 2017 jn.nutrition.org
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The risk of bias in included studies The included studies are described with respect to their risk of bias in Supplemental Table 3 . Methodologic limitations included a very small sample size, participantsÕ replacement, pseudo-random allocation, a high loss to follow-up, perprotocol analysis, and selective outcomes reporting. In many studies, because of poor reporting, unambiguous evaluation of the risk of bias was not possible, which often resulted in the description of some elements as unclear.
Effects of interventions-primary outcomes
Overweight and obesity. Only one RCT (30) (the CHOP study; n = 448) reported this outcome ( Table 3 ). The risk of becoming obese at the age of 6 y was significantly lower in the lower-protein formula group than in the higher-protein formula group (RR 0.44; 95% CI: 0.21, 0.91).
Fat mass and fat-free mass. The analysis of body composition by isotope dilution was performed in a subsample (n = 52) of 6-mo-old infants who were enrolled in the CHOP study (31) . Although correlations between the fat-mass z score (but not the fat-free mass z score) and both growth velocity and BMI were observed, fat-free mass and fat mass z scores did not differ between the higher-and lower-protein formula groups. In the study by Lonnerdal and Chen (26) , skin fold measurements were obtained at 5, 6, and 7 mo of age. The authors reported similar results for all study groups. However, no numeral data were available.
Anthropometric growth markers.
BMI. This outcome was reported at different time points in 4 publications (19, 27, 30, 32) (Table 3) . At 3 or 4 mo of age, there were no significant differences between the study groups. Starting at 6 mo of age, only one RCT (CHOP Study) reported data on BMI. BMI was significantly lower in the lower-protein formula group than in the higher-protein formula group at all time points (i.e., at 6, 12, and 24 mo and at 6 y).
BMI z scores. Only the CHOP study (unpublished data) reported BMI z scores (Table 3) . No significant differences were found at 3 and 6 mo of age between the lower-protein formula group and the higher-protein formula group. Starting at 12 mo of age, BMI z scores were significantly lower in the lower-protein formula group than in the higher-protein formula group at all time points (i.e., at 12 and 24 mo and at 6 y).
Mean weight. Twelve publications (18-20, 22-26, 29-32) reported mean weight at different time points (Figure 1 and Table 3 ). The pooled results of 4 RCTs (18, 19, 22, 24) showed no significant difference between the groups consuming lowerprotein and higher-protein formula at 3 mo of age (n = 998; MD, -0.07 kg; 95% CI: 20.15, 0.01). In one small (n = 13) trial by Zoppi et al. (29) , mean weight was significantly lower in infants fed formula with a lower-protein concentration than in those fed FIGURE 1 Forest plot of the effects of varying protein concentrations in infant formulas on the mean weight of infants at 3 mo of age. *Unpublished data;^combined results from 2 study arms. CHOP, EU Childhood Obesity Programme; F2.2, study group with formula protein concentration of 2.2 g/100 mL; F11, study group with formula protein concentration of 11.2 g/L; F13, study group with formula protein concentration of 13.3 g/L; IV, inverse variance.
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by guest on November 9, 2017 jn.nutrition.org formula with a higher-protein concentration at 5.5 mo of age; however, the difference between the groups was no longer significant when these infants were 10 mo old. The CHOP study reported a significantly lower mean weight in the group consuming lower-protein formula than in the group consuming higherprotein formula at 6 and 12 mo of age, but there was no significant difference between the groups at 24 mo and at 6 y. In one study (23) , this outcome was assessed at different child ages in the groups consuming lower-protein and higher-protein formula. Therefore, we found it improper to compare the results.
Mean weight z scores. Only the CHOP study (unpublished data) reported mean weight z scores (Table 3) . Mean weight z scores were significantly lower at 6 and 12 mo of age in the group consuming the lower-protein formula than in the group consuming the higher-protein formula; however, there were no significant differences between the groups at 3 mo, 24 mo, and 6 y of age.
Mean weight gain. The authors of almost all of the studies [except for the studies by Szajewska et al. (18) , Picone et al. (22) , and the CHOP study, unpublished data] reported gains in weight in a variety of ways (e.g., different units or different time intervals) (Figure 2 and Table 3 ). However, in almost all of the comparisons (regardless of the time intervals assessed), as well as when the results of some studies were pooled together into a meta-analysis, no statistically significant difference between the groups consuming lower-protein and higher-protein formulas was found in infants up to 12 mo of age.
Mean length/height. Mean length/height (absolute mean length/height or the z score for absolute length/height) was reported in 7 RCTs (18-20, 22, 24-26) (Figure 3 and Table 3 ). The pooled results of 4 RCTs (18, 19, 22, 24) revealed a significantly shorter length at 3 mo of age in the group consuming a lower-protein formula than in the group consuming the higherprotein formula (n = 998; MD, -0.27 cm; 95% CI: 20.52, 20.02). No significant differences between groups were found at any other time points (i.e., at 6 mo, 12 mo, and 24 mo, and 6 y of age). Three RCTs (20, 25, 26) provided only descriptive results (concluding that length was similar in all groups).
Length gain. Length gain up to 12 mo of age was assessed in 10 RCTs (20) (21) (22) (23) (24) (25) (26) (27) (28) (29) (Figure 4 and Table 3 ). Different units and different approaches to length measurements (i.e., length, crown-heel length, and crown-rump length) were used to express this outcome. The majority of available results showed a similar length gain in infants regardless of the protein concentration in the consumed formula.
In 2 studies performed by Lonnerdal and Chen (25, 26) , it was not clearly stated whether the authors described a similar mean weight and length or weight and length gain.
Head circumference. In 5 RCTs (18, 22, (24) (25) (26) , data regarding head circumference were available ( Figure 5) . The pooled results of 3 RCTs (18, 22, 24) showed no significant difference in head circumference between the groups consuming lower-protein and higher-protein formula at 12 wk of age (MD, 20.31 cm; 95% CI: 20.63, 0.02). However, significant heterogeneity was found (I 2 = 81%). The observed heterogeneity was not explained by the subgroup analysis based on the amount of protein in milk formulas, which was performed as originally planned in the protocol. We also considered different measurement techniques as a potential source of the identified heterogeneity. However, the authors did not report how the measurements were obtained. In 2 studies by Lonnerdal and Chen (25, 26) , the authors reported a similar mean head circumference in all study groups (numerical data were not shown).
Head circumference gain. In the study by Turck et al. (27) , the daily gain in head circumference (millimeters per day) at monthly intervals was described, showing a similar growth rate in both study groups. In the study by Zoppi et al. (23) , the mean increase in head circumference was evaluated in the group consuming higher-protein formula only. In another report (28) , the mean daily gain in head circumference was described as normal.
Weight-for-length z scores. Weight-for-length z scores were analyzed in the CHOP study [(unpublished data) Table 3 ]. The weight-for-length z scores were significantly higher at 6, 12, and 24 mo of age in the group consuming higher-protein formula than in the group consuming lower-protein formula.
Other. Other anthropometric assessments were reported in some of the included trials (particularly an early assessment of growth at 2, 4, and 8 wk of age; evaluation of weight and length gain at monthly intervals; etc.). However, we found the results of these trials to be irrelevant to our review.
Secondary outcomes
Our secondary outcomes were only partially addressed in 2 studies. A summary of these findings is presented in Table 4 .
Discussion
Summary of the evidence. This review revealed that the vast majority of identified studies evaluated only short-term outcomes related to infant growth. The gathered evidence suggests that during the first year of life, different protein concentrations in infant formulas do not seem to affect infantsÕ linear growth significantly apart from a transient effect on mean length during the first months of life. Data with respect to weight and weight gain suggest similar growth in the first months of life, with a lower mean weight (and weight z score) obtained in the infants fed lower-protein formulas from ;6 mo until 12 mo of age only. A significantly lower BMI associated with the intake of lowerprotein formula was firmly observed in 12-mo-old infants and in children up until early school age. No conclusions with regard to the effects of formula protein concentration on body composition can be formulated. We have identified only one RCT (the CHOP study) that assessed the outcomes of interest after infancy. The intake of lower-protein formula during infancy was observed to reduce the risk of obesity at the age of 6 y in this study. However, these findings need to be interpreted with caution, because this is a single report, and some methodologic limitations of the study were identified.
FIGURE 4
Forest plot of the effects of varying protein concentrations in infant formulas on the mean length gain of infants from 3 to 6 mo and from 6 to 12 mo of age.^Combined results from 2 study arms. F13, study group with formula protein concentration of 13 g/L; F15, study group with formula protein concentration of 15 g/L; IV, inverse variance.
FIGURE 5
Forest plot of the effects of varying protein concentrations in infant formulas on the mean head circumference of infants at 3 mo of age.^Combined results from 2 study arms. F2.2, study group with formula protein concentration of 2.2 g/100 mL; F11, study group with formula protein concentration of 11.2 g/L; F13, study group with formula protein concentration of 13.3 g/L; IV, inverse variance.
Strengths and limitations. The major strength of our review is that it collates the largest number of studies, to our knowledge, available on the effects of varying protein concentrations in infant formulas on growth, body composition, and the later risk of obesity. We used a rigorous systematic review methodology proposed by the Cochrane Collaboration. We used several methods to reduce bias from the initial preparatory stage until the final report (i.e., protocol registration, comprehensive literature search, duplicate data abstraction, and prespecified criteria for methodologic assessment and analysis). We did not impose restrictions by language or year of publication. Attempts were made to identify unpublished trials. However, this review has some limitations. The methodologic quality of the included trials varied. Potential limitations include unclear sequence generation, unclear allocation concealment and blinding, small sample sizes, lack of sample size calculations, and high dropout rates in some trials, including the CHOP trial. Despite the fact that a number of trials met the inclusion criteria, our conclusions after the infancy period are based solely on the results of one RCT (the only experimental study with a large sample size and longer follow-up). It is worth mentioning that the sample sizes of the included studies varied, and that sample size in the CHOP study was greater than the total number of participants of all other included studies. We observed a great deal of heterogeneity in the protein concentrations in the formulas used in different studies, with the protein amount being the same in groups consuming lower-and higher-protein formula, depending on the study in some cases. Therefore, our review cannot provide an answer to the question of what the particular and optimal amount of protein to be included in infant formulas should be.
Another important aspect raised by our review is that not only protein quantity, but also protein quality, must be taken into account to secure a sufficient amount of essential amino acids to support adequate growth and safety in infants. Studies that use the Indicator Amino Acid Oxidation method to determine the actual requirement of each essential amino acid in neonates have shown that infant formulas that are currently used may not contain the optimal amino acid composition and may provide an amount of essential amino acids that is too high (35) (36) (37) . However, a detailed analysis of the amino acid content of formula was outside the scope of our review. Also, we have excluded from our analysis a number of studies in which additional differences between the groups were present, such as enriched milk formula (with a-lactalbumin, for example) or formula with extra components added (see exclusion criteria), apart from quantitative protein modifications, differences in the whey-to-casein ratio, and other differences in composition secondary to the protein amount changes (in order to achieve an isocaloric formula). These restrictive criteria were developed to reduce the great heterogeneity between the included studies. However, we realize that these data may be a substantial addition to this complex issue. Finally, we analyzed only one aspect of protein intake provided by milk formula consumption, whereas other sources of protein in the diet also play an important role after the introduction of complementary feeding.
Agreement and disagreement with other studies or reviews. The findings of this review are in accordance with 2 recently published reviews. The first review by Hornell et al. (38) , published in 2013, focused on protein intake in the diet (not only in milk formula) of children of different ages (0-18 y) and its relation to health based on both experimental and observational studies. The authors concluded that higher protein intake during infancy is associated with increased growth, a higher BMI during childhood, and an increased risk of being overweight later in life. The second review by Abrams et al. (39) , published when this manuscript was in the final stages of preparation, addressed the effect of the intake of low-protein and low-energy formula by full-term infants on growth. Six publications were included in that review. Based on the findings from 4 RCTs, the authors concluded that the use of infant formulas with concentrations of protein and energy slightly below historical standards in the United States results in adequate growth during infancy and early childhood. The authors also stated that ''Further long-term research is needed to assess the impact of the use of lower-protein and/or lower-energy products, especially for nutritionally at-risk populations such as preterm infants and infants who are born small for gestational age'' (39) . Although the authors asked a similar question to the one that is the subject of our review, their approach differed. The search was limited to 3 electronic databases only (i.e., Medline, Cochrane, and the Cumulative Index to Nursing and Allied Health Literature). Furthermore, the set of key words used for searching differed, as well as the inclusion and exclusion criteria, resulting in the differences observed in the number of identified trials (4 studies in the review by Abrams et al. (39) compared with 12 trials identified in this review). This was not unexpected, because it is well known that small differences in search strategies may result in substantial differences in the set of trials identified. Nevertheless, taken together, all 3 reviews clearly prove how complex the issue of protein intake can be and leave room for more evidence and other systematic analyses to answer the questions that remain unanswered. (32) IGF-I axis Higher protein intake stimulates IGF-I axis and insulin release CHOP (33, 34) Kidney size (at 6 mo of age) Significantly increased kidney size in infants who consumed a higher-protein formula IGF-I in part mediates protein-induced kidney growth Effect of higher protein intake during early infancy on long-term kidney function requires further evaluation
The evidence is insufficient for assessing the effects of reducing protein concentration in infant formulas on longterm outcomes, but, if confirmed, this could represent a promising intervention for reducing the risk of overweight and obesity in children. In view of the limited available evidence, more studies replicating the effects on long-term health outcomes are needed. Careful analysis of observational studies that have assessed long-term outcomes of interest may provide a valuable addition to the limited experimental evidence.
